Announcement of Availability for Capivasertib (AZD5363)

September 07, 2021

The Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using capivasertib (AZD5363), a potent and selective ATP-competitive oral inhibitor of all three AKT isoforms, which is being developed by CTEP as an anticancer agent in collaboration with AstraZeneca Pharmaceuticals. CTEP will also consider requests to supply capivasertib for nonclinical studies. All clinical and nonclinical researchers possessing an interest in working with the agent are welcome to apply. Proposals for clinical trials should be supported by a strong rationale and robust preclinical data (see “Components of a Competitive Letter of Intent” at http://ctep.cancer.gov/protocolDevelopment/lois_concepts.htm).

All proposals approved by CTEP will be sent to the industry collaborator for a commitment to supply drug for the study.

Questions may be addressed to Dr. Rabih Said, Medical Officer, Investigational Drug Branch, CTEP, DCTD, NCI (rabih.said@nih.gov).

For more information please see related documents below.